Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1257-1263

  Lu, Yen Shen ^a   Chen, Dar Ren ^b   Tseng, Ling Min ^c   Yeh, Dah Cherng ^d   Chen, Shou Tung ^b   Hsieh, Chia Ming ^e   Wang, Hwei Chung ^f   Yeh, Hsien Tang ^g   Kuo, Sung Hsin ^a   Huang, Chiun Sheng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e TAIWAN ADVENTIST HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g LOTUNG POH AI HOSPITAL   (Taiwan)

Author keywords

Capecitabine; Cisplatin; Docetaxel; Locally advanced breast cancer; Neoadjuvant chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; EDEMA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LYMPH NODE METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSPECTIVE STUDIES; TAXOIDS;

EID: 79959617879     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1401-2     Document Type: Article

References (42)

1. Taiwan Cancer Registry Annual Report (2006) Department of Health, the Executive Yuan, Taiwan ROC, Available at http://crs.cph.ntu.edu.tw. Accessed Oct 19, 2009
2. Huang CS, Chang KJ, Shen CY (2001) Breast cancer screening in Taiwan and China. Breast Disease 13:41-48
3. Franceschini G, Terribile D, Fabbri C et al (2007) Management of locally advanced breast cancer. Mini-review. Minerva Chir 62:249-255
4. Levin M (2001) The role of taxanes in breast cancer treatment. Drugs Today 37:57-65
5. Tusquets I, Estévez LG, Alvarez I et al (2007) The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials. Clin Breast Cancer 7:764-774 (Pubitemid 350089902)
6. Di Leo A, Gancberg D, Larsimont D et al (2002) HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116 (Pubitemid 34517647)
7. Pivot X, Asmar L, Hortobagyi GN (1999) The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 15:381-386
8. Witters LM, Santala SM, Engle L et al (2003) Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am J Clin Oncol 26:50-54 (Pubitemid 36205897)
9. Jones SE, Erban J, Overmoyer B et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
10. Burris HA III (1999) Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 26:1-6
11. Lin YC, Chang HK, Wang CH et al (2000) Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. Anticancer Drugs 11:617-621
12. Baselga J, Tabernero JM (2001) Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 6(3):26-29 (Pubitemid 32423183)
13. Rivera E, Mejia JA, Arun BK et al (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455-1461 (Pubitemid 351459423)
14. Maher JF, Villalona-Calero MA (2002) Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2:287-293 (Pubitemid 34196271)
15. O'Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823 (Pubitemid 34651510)
16. Lebowitz PF, Eng-Wong J, Swain SM et al (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10:6764-6769 (Pubitemid 39383024)
17. Bellet M, Munoz M, Suarez M et al (2006) Phase II study of capecitabine (C) in combination with docetaxel (D) as neoadjuvant treatment in patients with locally advanced breast cancer (IIIA and IIIB stage) including biological correlates. Proc Am Soc Clin Oncol 24:18S (abstr 664)
18. Lee KS, Ro J, Nam BH et al (2008) A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 109:481-489 (Pubitemid 351692059)
19. Crown CP (2001) The platinum agents: a role in breast cancer treatment? Semin Oncol 28(3):28-37
20. Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112 (Pubitemid 13023531)
21. Sledge GW Jr, Loehrer PJ Sr, Roth BJ et al (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814 (Pubitemid 19089062)
22. Mechl Z, Sopkova B (1984) CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer. Neoplasma 31:431-435 (Pubitemid 14046553)
23. Crown J, Pegram M (2003) Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 79(Suppl 1):S11-S18
24. Kariya S, Ogawa Y, Nishioka A et al (2002) Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer. Oncol Rep 9:1345-1349
25. Lin YC, Chang HK, Chen JS et al (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 37:23-29
26. Spielmann M, Llombart A, Zelek L et al (1999) Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 10:1457-1460 (Pubitemid 30017055)
27. Jacobs C, Bertino J, Goffinet D et al (1978) 24-hour infusion of cisplatin in head and neck cancer. Cancer 42:2133-2140
28. Hsu C, Huang CS, Chao TY et al (2002) Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. Cancer 95:2044-2050 (Pubitemid 35253364)
29. Gralla RJ, Osoba D, Kris MG et al for the American Society of Clinical Oncology (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971-2994
30. Recht A, Edge SB, Solin LJ et al (2001) Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569 (Pubitemid 32203717)
31. Simon R (1993) Design and conduct of clinical trials. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and Practice of oncology, 4th edn. Philadelphia, Lippincott, pp 418-440
32. Buzdar AU (2007) Preoperative chemotherapy treatment of breast cancer - A review. Cancer 110:2394-2407
33. von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685 (Pubitemid 46179457)
34. Hudis C, Modi S (2007) Preoperative chemotherapy for breast cancer miracle or mirage? JAMA 298:2665-2667
35. Layman RM, Thomas DG, Griffith KA et al (2007) Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 13:4092-4097 (Pubitemid 47105970)
36. Lee YJ, Doliny P, Gomez-Fernandez C et al (2004) Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 5:371-376 (Pubitemid 40109645)
37. Franco SX, Perez A, Frankel C et al (2005) Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). Proc Am Soc Clin Oncol 23:16S (abst 876)
38. Manga GP, Shahi PK, Ureña MM et al (2009) Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer. Breast Cancer, Published online June 24, 2009. doi:10.1007/s12282-009-0136-6
39. Al-Tweigeri TA, Ajarim DS, Alsayed AA et al (2009) Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/ docetaxel in locally advanced breast cancer. Med Oncol. Published online June 13, 2009. doi:10.1007/s00280-009-1049-y
40. Nieto Y, Aramendía JM, Espinós J et al (2010) Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Cancer Chemother Pharmacol 65:457-465
41. von Minckwitz G, Rezai M, Loibl S et al (2010) Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 28:2015-2023
42. Jinno H, Sakata M, Hayashida T et al (2010) A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/ cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer. Ann Oncol 21:1262-1266